Cytotoxic T lymphocyte activation via antigen presentation pathway

The “Cytotoxic T lymphocyte activation via antigen presentation pathway” describes the molecular and cellular events that occur when cytotoxic T lymphocytes (CD8+ T cells) are activated upon recognition of foreign or abnormal peptides presented by antigen-presenting cells via major histocompatibility complex class I (MHC-I) molecules. Activation requires at least two signals: (1) engagement of the T cell receptor (TCR) with peptide-MHC-I on the antigen-presenting cell and (2) co-stimulatory signals such as those from the interaction of CD28 on the T cell with B7 family ligands (CD80/CD86) on the antigen-presenting cell[2][4][7]. This process initiates signaling cascades that drive T cell proliferation, differentiation, cytolytic effector function—including release of perforin and granzymes to induce target cell death—and clonal expansion[1][3][7][10]. Regulatory mechanisms such as CTLA-4 expression provide a check to prevent over-activation and autoimmunity[4]. The pathway is crucial in eliminating virus-infected or cancerous cells[10]. This entry does not reflect a single molecule or receptor target but instead a complex immunological signaling process. Therefore, it is not considered a canonical therapeutic “target” (such as a receptor, enzyme, or transporter), but understanding and modulation of this pathway are central to immuno-oncology and related drug development.

Not applicable; refers to the pathway/process, not a single molecular target